164 results
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
20 Mar 24
RepliCel announces a Letter of Intent for Asset Purchase Agreement
4:38pm
are based on RepliCel's innovative technology, utilizing cell populations isolated from a patient's healthy hair follicles.
The Company's cell therapy
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
on RepliCel's innovative technology which utilizes cells isolated from a patient's own healthy hair follicles. These products are built on the Company's
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
of a specific cell type which the Company believes is critical to normal function. All treatments under development are based on RepliCel's innovative
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
19 Oct 23
Current report (foreign)
1:45pm
candidates are based on RepliCel’s innovative technology, utilizing cell populations isolated from a patient’s healthy hair follicles.
1 | Page
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
4 Oct 23
RepliCel Provides Default Status Update and Announces Shareholder Approval of Equity Incentive Plan
2:23pm
and function. These cell therapy product candidates are based on RepliCel’s innovative technology, utilizing cell populations isolated from a patient’s
6-K
EX-99.2
2ntl81gyad 4dsu
13 Sep 23
RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration Proceedings
5:32pm
6-K
EX-99.1
fcm5f5 j6d
13 Sep 23
RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration Proceedings
5:32pm
6-K
EX-99.1
ndnrw 9b5kk9b
7 Sep 23
Current report (foreign)
12:26pm
6-K
EX-99.1
ki3nd0
29 Aug 23
RepliCel announces the passing of long time Chief Financial Officer Simon Ma; David Kwok is appointed Chief Financial Officer
1:14pm
6-K
EX-99.2
8p1ox0v
17 Aug 23
Annual General and Special Meeting
11:22am
6-K
EX-99.4
kfvfi7y
17 Aug 23
Annual General and Special Meeting
11:22am
6-K
EX-99.2
yjb4xyrndr
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.1
rrqkmo 322
18 May 23
RepliCel Applies to Extend Warrant and Stock Option Expiry Dates and Announces Grant of Stock Options
1:58pm
6-K
EX-99.5
ko2j muwyvzggsv3
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.2
8o7bgvqrj43z9r4fq
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.1
12ysk1oaspokghc5x
25 Oct 22
Current report (foreign)
12:27pm
6-K
EX-99.2
j7gy dmdonjx
25 Oct 22
Current report (foreign)
12:27pm
20-F/A
ctukg cki6hg
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.1
1395mvcork6
6 Sep 22
RepliCel Announces Non-brokered Private Placement
2:35pm